Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology

Seferović, Petar M., Petrie, Mark C., Filippatos, Gerasimos S., Anker, Stefan D., Rosano, Giuseppe, Bauersachs, Johann, Paulus, Walter J., Komajda, Michel, Cosentino, Francesco, de Boer, Rudolf A., Farmakis, Dimitrios, Doehner, Wolfram, Lambrinou, Ekaterini, Lopatin, Yuri, Piepoli, Massimo F., Theodorakis, Michael J., Wiggers, Henrik, Lekakis, John, Mebazaa, Alexandre, Mamas, Mamas A., Tschöpe, Carsten, Hoes, Arno W., Seferović, Jelena P., Logue, Jennifer, McDonagh, Theresa, Riley, Jillian P., Milinković, Ivan, Polovina, Marija, van Veldhuisen, Dirk J., Lainscak, Mitja, Maggioni, Aldo P., Ruschitzka, Frank, McMurray, John J.V.·2018·European Journal of Heart Failure
DOI 10.1002/ejhf.1170

Cited by (704)

Items 101–200 of 704

  1. Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study
    Ify R. Mordi, R Thomas Lumbers, Colin N.A. Palmer, Ewan R. Pearson, Naveed A. Sattar, Michael Vaclav Holmes, Chim Choy Lang · 2021 · Diabetes Care
  2. Sex Differences of the Diabetic Heart
    Natacha Fourny, Christophe Beauloye, Monique Bernard, Sandrine Horman, Martine Desrois, Luc Bertrand · 2021 · Frontiers in Physiology
  3. Multimodality imaging approach to left ventricular dysfunction in diabetes: an expert consensus document from the European Association of Cardiovascular Imaging
    Thomas Hugh Marwick, Alessia Gimelli, Sven Plein, Jeroen Joost Bax, Philippe Charron, Victoria Delgado, Erwan Donal, Patrizio Lancellotti, Eylem Levelt, Pál Maurovich‐Horvat et al. · 2021 · European Heart Journal - Cardiovascular Imaging
  4. Left Ventricular Diastolic Dysfunction in Type 2 Diabetes—Progress and Perspectives
    Elena-Daniela Grigorescu, Cristina-Mihaela Lăcătușu, Mariana Floria, Bogdan Mircea Mihai, Ioana Crețu, Laurențiu Șorodoc · 2019 · Diagnostics
  5. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes
    Jasper Tromp, Adriaan A. Voors, Abhinav Sharma, João Pedro Ferreira, Wouter Ouwerkerk, Hans L. Hillege, Karla F. Arevalo Gomez, Kenneth Dickstein, Stefan D. Anker, Marco Metra et al. · 2020 · JACC Heart Failure
  6. Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors
    Adina Braha, Bogdan Timar, Laura Diaconu, Raluca Lupușoru, Lucian Vasiluță, Alexandra Christa Sima, Adrian Vlad, Mircea Munteanu, Alin Albai, Daniela Cipu et al. · 2019 · Diabetes Metabolic Syndrome and Obesity
  7. Type 2 Diabetes Increases the Long-Term Risk of Heart Failure and Mortality in Patients with Atrial Fibrillation
    Marija M. Polovina, Lars H. Lund, Dijana Đikić, Ivana Petrović‐Đorđević, Gordana Krljanać, Ivan Milinković, Ivana Veljić, Massimo Francesco Piepoli, Giuseppe M.C. Rosano, Arsen D. Ristić et al. · 2019 · European Journal of Heart Failure
  8. Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis
    Aleksandra Gamrat, Michał A. Surdacki, Bernadeta Chyrchel, Andrzej Surdacki · 2020 · Journal of Clinical Medicine
  9. Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
    Andrija S. Pavlovic, Marija M. Polovina, Arsen D. Ristić, Jelena P. Seferović, Ivana Veljić, Dejan S. Simeunović, Ivan Milinković, Gordana Krljanać, Milika Ašanin, Irena Ostric et al. · 2018 · European Journal of Preventive Cardiology
  10. Reappraisal on pharmacological and mechanical treatments of heart failure
    Bo Liang, Yu-Xiu Zhao, Xiaoxiao Zhang, Hui-Ling Liao, Ning Gu · 2020 · Cardiovascular Diabetology
  11. Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
    Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, Maciej Błażej Hajduga, Jan Bujok, Celina Pająk, Michał Ćwiertnia · 2020 · Heart Failure Reviews
  12. Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction
    Dong-Hyuk Cho, Byung‐Su Yoo · 2021 · Heart Failure Clinics
  13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
    Shaline D. Rao · 2021 · Advances in Therapy
  14. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
    Pérez-Belmonte, Luis M., Sanz-Cánovas, Jaime, García de Lucas, María D., Ricci, Michele, Avilés-Bueno, Beatriz, Cobos-Palacios, Lidia, Pérez-Velasco, Miguel A., López-Sampalo, Almudena, Bernal-López, M. Rosa, Jansen-Chaparro, Sergio et al. · 2022 · Frontiers in Endocrinology
  15. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials
    Kris Kumar, Babikir Kheiri, Timothy F. Simpson, Mohammed Osman, Hind W. Rahmouni · 2020 · The American Journal of Medicine
  16. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
    Benedetta Maria Bonora, Saula Vigili de Kreutzenberg, Angelo Avogaro, Gian Paolo Fadini · 2019 · Cardiovascular Diabetology
  17. Characterising an Alternative Murine Model of Diabetic Cardiomyopathy
    Mitchel Tate, Darnel Prakoso, Andrew M. Willis, Cheng Yun Peng, Minh Deo, Cheng Xue Qin, Jesse L. Walsh, David M. Nash, Charles D. Cohen, Alex K. Rofe et al. · 2019 · Frontiers in Physiology
  18. Gentiopicroside alleviates cardiac inflammation and fibrosis in T2DM rats through targeting Smad3 phosphorylation
    Xiaozhou Zou, Yiwen Zhang, Zongfu Pan, Xiao-ping Hu, Yin-ning Xu, Zhong-jie Huang, Zhiyong Sun, Meng‐nan Yuan, Jiana Shi, Ping Cheong Huang et al. · 2022 · Phytomedicine
  19. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials
    Dario Giugliano, Maria Ida Maiorino, Miriam Longo, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito · 2019 · Endocrine
  20. Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes
    Silverii, Giovanni Antonio · 2024 · Diabetes, Obesity and Metabolism
  21. GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
    Han‐Mo Yang · 2025 · Journal of Clinical Medicine
  22. Application of Animal Models in Diabetic Cardiomyopathy
    Wang Soo Lee, Jaetaek Kim · 2021 · Diabetes & Metabolism Journal
  23. Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology
    Garnham, Jack O., Roberts, Lee D., Espino‐Gonzalez, Ever, Whitehead, Anna, Swoboda, Peter P., Koshy, Aaron, Gierula, John, Paton, Maria F., Cubbon, Richard M., Kearney, Mark T. et al. · 2020 · Journal of Cachexia Sarcopenia and Muscle
  24. Circulating branched‐chain amino acids and incident heart failure in type 2 diabetes: The Hong Kong Diabetes Register
    Lee‐Ling Lim, Eric S. H. Lau, Erik Fung, Heung Man Lee, Ronald C.W., Claudia H.T. Tam, Willy K.K. Wong, Alex C.W. Ng, Elaine Chow, Andrea O. Y. Luk et al. · 2020 · Diabetes/Metabolism Research and Reviews
  25. Skeletal Muscle Atrophy in Heart Failure with Diabetes: From Molecular Mechanisms to Clinical Evidence
    Nathanael Wood, Sam Straw, Mattia Scalabrin, Lee D. Roberts, Klaus K. Witte, Thomas Scott Bowen · 2020 · ESC Heart Failure
  26. Molecular mechanisms of action of resveratrol in modulation of diabetic and non-diabetic cardiomyopathy
    Irshad Ahmad, Muddasarul Hoda · 2020 · Pharmacological Research
  27. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
    Preman Kumarathurai, Ahmad Sajadieh, Christian Anholm, Ole Peter Kristiansen, Steen B. Haugaard, Olav Wendelboe Nielsen · 2021 · Cardiovascular Diabetology
  28. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern‐En Chiang, Kwo-Chang Ueng, Ting‐Hsing Chao, Tsung‐Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih‐Hsien Sung, Hung‐I Yeh, Yi‐Heng Li, Ping‐Yen Liu et al. · 2020 · Journal of the Chinese Medical Association
  29. Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes
    Jie Tao, Dasen Sang, Libo Zhen, Xinxin Zhang, Yuejun Li, Guodong Wang, Shuohua Chen, Shouling Wu, Wenjuan Zhang · 2023 · Cardiovascular Diabetology
  30. Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality
    Frank Lezoualc’h, Lina Badimón, Hana E. Baker, Monique Bernard, Gábor Czibik, Rudolf A. de Boer, Thomas d’Humières, Micheline Kergoat, Mark C. Kowala, Jennifer Rieusset et al. · 2022 · Cardiovascular Research
  31. Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial
    Luca Faconti, Charlotte Elizabeth Mills, V. Govoni, Haotian Gu, S. V. Morant, Benju Jiang, John Kennedy Cruickshank, Andrew James Webb · 2018 · British Journal of Clinical Pharmacology
  32. Cost-Effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure
    Odette S. Reifsnider, Anuraag R. Kansal, Jennifer Franke, Joseph Hyungwoo Lee, Jyothis Thomas George, Martina Brueckmann, Stefan Kaspers, Sarah B. Brand, Anastasia Ustyugova, Stephan Linden et al. · 2020 · ESC Heart Failure
  33. Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
    Miriam Longo, Lorenzo Scappaticcio, Paolo Cirillo, Antonietta Maio, Raffaela Maria Carotenuto, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito · 2022 · Biomolecules
  34. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Preserved Ejection Fraction: Cardiac Structure and Function, Clinical Outcomes, and Response to Sacubitril/Valsartan in PARAGON-HF
    Mats Christian Højbjerg Lassen, John W. Ostrominski, Brian Lee Claggett, Milton Packer, Michael R. Zile, Akshay Suvas Desai, Amil M. Shah, Maja Čikeš, Béla Péter Merkely, Mauro Gori et al. · 2024 · European Journal of Heart Failure
  35. Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure
    Chen Gao, Shuxun Vincent Ren, Junyi Yu, Ulysis Hugo Baal, Dung Luong Thai, John Lu, Chunyu Zeng, Hai Yan, Yibin Wang · 2019 · JACC Basic to Translational Science
  36. Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
    Chan‐Hee Jung, Ji‐Oh Mok · 2020 · Endocrinology and Metabolism
  37. Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese japanese subjects in a general community
    Kazutoshi Hirose, Koki Nakanishi, Masao Daimon, Naoko Sawada, Yuriko Yoshida, Kentaro Iwama, Yuko Yamamoto, Jumpei Ishiwata, Megumi Hirokawa, Katsuhiro Koyama et al. · 2021 · Cardiovascular Diabetology
  38. Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure
    Michele Correale, Pietro Mazzeo, Adriana Mallardi, Alessandra Leopizzi, Lucia Tricarico, Martino Fortunato, Michele Magnesa, Salvatore Tucci, Pasquale Maiellaro, Giuseppe Pastore et al. · 2021 · Cardiovascular Drugs and Therapy
  39. Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
    Yoshiaki Kubota, Wataru Shimizu · 2022 · JACC Asia
  40. Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study
    Giuseppe Palmiero, Arturo Cesaro, Raffaele Galiero, Giuseppe Loffredo, Alfredo Caturano, Erica Vetrano, Luca Rinaldi, Teresa Salvatore, Roberto Ruggiero, Maria Rosaria Di Palo et al. · 2023 · Diabetes Research and Clinical Practice
  41. Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
    Weronika Frąk, Joanna Hajdys, Ewa Radzioch, Magdalena Szlagor, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2023 · Biomedicines
  42. Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism
    Zhen Zhang, Jing Wang, Yingwei Zhu, Hui Zhang, Hongxin Wang · 2019 · Molecular Medicine Reports
  43. Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center
    Iwona Świątkiewicz, Neeja Patel, MaryAnn Villarreal-Gonzalez, Pam R. Taub · 2024 · BMC Medicine
  44. Development and Validation of a Novel Model for Predicting the 5‐Year Risk of Type 2 Diabetes in Patients with Hypertension: A Retrospective Cohort Study
    Xintian Cai, Qing Zhu, Ting Wu, Bin Zhu, Xiayire Aierken, Ayguzal Ahmat, Nanfang Li · 2020 · BioMed Research International
  45. Miocardiopatía diabética
    Ana Lorenzo-Almorós, J.M. Cepeda-Rodrigo, Óscar Lorenzo · 2020 · Revista Clínica Española
  46. Dual-specificity phosphatase 12 attenuates oxidative stress injury and apoptosis in diabetic cardiomyopathy via the ASK1-JNK/p38 signaling pathway
    Huan Li, Qin Yang, Zhen Huang, Cui Liang, Dianhong Zhang, Hui-Ting Shi, Jiaqi Du, Binbin Du, Yanzhou Zhang · 2022 · Free Radical Biology and Medicine
  47. Systematic Review of Sodium-Glucose Cotransporter 2 Inhibitors: A Hopeful Prospect in Tackling Heart Failure-Related Events
    Buena Aziri, Edin Begić, Slobodan Јаnkovic, Zorica Mladenović, Bojan Stanetić, Tamara Kovačević-Preradović, Amer Iglica, Aida Mujaković · 2023 · ESC Heart Failure
  48. Analysis for warning factors of type 2 diabetes mellitus complications with Markov blanket based on a Bayesian network model
    Liu, Siying, Zhang, Runtong, Shang, Xiaopu, Li, Weizi · 2020 · Computer Methods and Programs in Biomedicine
  49. The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy
    Fatih Mehmet Gür, İbrahim Aktaş · 2021 · Tissue and Cell
  50. Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis
    Amir Razaghizad, Emily Oulousian, Varinder K. Randhawa, João Pedro Ferreira, James M. Brophy, Stephen John Greene, Julian Guida, Gary Michael Felker, Marat Fudim, Michael A. Tsoukas et al. · 2022 · Journal of the American Heart Association
  51. NADPH Oxidase Mediates Oxidative Stress and Ventricular Remodeling through SIRT3/FOXO3a Pathway in Diabetic Mice
    Jiuchun Qiu, Daiqi Liu, Pengsha Li, Lingling Zhou, Lu Zhou, Xing Liu, Yue Zhang, Meng Yuan, Gary Tse, Guangping Li et al. · 2022 · Antioxidants
  52. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
    Pratley, Richard E., Husain, Mansoor, Lingvay, Ildiko, Pieber, Thomas R., Mark, Thomas, Saevereid, Hans A., Møller, Daniel Vega, Zinman, Bernard, the DEVOTE Study Group · 2019 · Cardiovascular Diabetology
  53. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
    Oliver Schnell, Katharine D. Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández‐Fernández, Thomas M. Forst, Juan P. Frías, James R. Gavin, Francesco Giorgino et al. · 2024 · Cardiovascular Diabetology
  54. Effects of SGLT2-Inhibitors on Comprehensive Geriatric Assessment, Biomarkers of Oxidative Stress, and Platelet Activation in Elderly Diabetic Patients with Heart Failure with Preserved Ejection Fraction
    Marcello Magurno, Velia Cassano, Francesco Maruca, Carlo Alberto Pastura, Marcello Divino, Federica Fazio, Giandomenico Severini, Elvira Clausi, Giuseppe Armentaro, Sofia Miceli et al. · 2024 · International Journal of Molecular Sciences
  55. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology
    Seferović, Peter, Farmakis, Dimitrios, Bayes-Genis, Antoni, Ben Gal, Tuvia, Böhm, Michael, Chioncel, Ovidiu, Ferrari, Roberto, Filippatos, Gerasimos, Hill, Loreena, Jankowska, Ewa et al. · 2022 · European Journal of Heart Failure
  56. Chapter 1: The Burden of Heart Failure
    Richard E. Pratley, Xuan Guan, Richard J. Moro, Rodrigo do Lago · 2024 · The American Journal of Medicine
  57. NR4A2 alleviates cardiomyocyte loss and myocardial injury in rats by transcriptionally suppressing CCR5 and inducing M2 polarization of macrophages
    Huangtai Miao, Xiaoying Li, Can Zhou, Ying Jie Liang, Deshun Li, Qingwei Ji · 2021 · Microvascular Research
  58. Subclinical systolic dysfunction detected by 2D speckle tracking echocardiography in adults with diabetes mellitus: systematic review and meta-analysis of 6668 individuals with diabetes mellitus and 7218 controls
    Seyed‐Mohammad Ghoreyshi‐Hefzabad, Prajith Jeyaprakash, Ha Q. Vo, Alpa Gupta, Koya Ozawa, Faraz K. Pathan, Kazuaki Negishi · 2023 · The International Journal of Cardiovascular Imaging
  59. Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
    Olga N. Dzhioeva, Evgeny Belyavskiy · 2020 · Therapeutics and Clinical Risk Management
  60. Insulin Resistance, a Risk Factor for Alzheimer’s Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach
    Flora Affuso, Filomena Micillo, Sergio Fazio · 2024 · Biomedicines
  61. Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
    Neal Pohlman, Prem N Patel, Utibe R. Essien, Jingjing Tang, Joshua J. Joseph · 2025 · The Journal of Clinical Endocrinology & Metabolism
  62. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
    Clara García-Carro, Ander Vergara, Irene Agraz, Conxita Jacobs-Cachá, Eugènia Espinel, Daniel Serón, María José Soler · 2019 · Journal of Clinical Medicine
  63. Sunitinib-induced cardiac hypertrophy and the endothelin axis
    Joevin Sourdon, Caterina Facchin, Anaïs Certain, Thomas Viel, Blaise Robin, Franck Lager, Carmen Marchiol, Daniel Balvay, Thulaciga Yoganathan, Judith Favier et al. · 2021 · Theranostics
  64. Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction
    Yuxi Sun, Jinping Si, Jiaxin Li, Mengyuan Dai, Emma King, Xinxin Zhang, Yanli Zhang, Yunlong Xia, Gary Tse, Ying Liu · 2021 · Frontiers in Cardiovascular Medicine
  65. Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction
    Hidemi Sorimachi, Kazunori Omote, Barry A. Borlaug · 2021 · Heart Failure Clinics
  66. Preventing new-onset heart failure: Intervening at stage A
    Bharathi Upadhya, Shriram Hegde, Manasi Tannu, Richard Brandon Stacey, Andreas P. Kalogeropoulos, Douglas D. Schocken · 2023 · American Journal of Preventive Cardiology
  67. Prognostic Significance of Elevated Left Ventricular Filling Pressures with Exercise: Insights from a Cohort of 14,338 Patients
    Christina L. Luong, Vidhu Anand, Ratnasari Padang, Jae K. Oh, Adelaide Maria Arruda-Olson, Jared Glynn Bird, Cristina Pislaru, Jeremy J. Thaden, Sorin V. Pislaru, Patricia A. Pellikka et al. · 2023 · Journal of the American Society of Echocardiography
  68. Prevalence and Predictors of Left Ventricular Diastolic Dysfunction in Malaysian Patients With Type 2 Diabetes Mellitus Without Prior Known Cardiovascular Disease
    Kok Han Chee, Kok Leng Tan, Luqman Ibrahim, Shahrizal Shudim Saiful, Yee Yean Chew, Karuthan Chinna, Alexander Tong Boon Tan · 2021 · Frontiers in Cardiovascular Medicine
  69. Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
    Giovanna Gallo, Massimo Volpe · 2024 · International Journal of Molecular Sciences
  70. Predictors of heart failure development in type 2 diabetes
    Subodh Verma, Abhinav Sharma, Naresh Kanumilli, Javed Butler · 2019 · Current Opinion in Cardiology
  71. Microvascular Disease and Heart Failure with Reduced and Preserved Ejection Fraction in Type 2 Diabetes
    Ify R. Mordi, Aaron Tee, Colin N. Palmer, Rory J. McCrimmon, Alex S. F. Doney, Chim Choy Lang · 2020 · ESC Heart Failure
  72. Diastolic dysfunction in a pre-clinical model of diabetes is associated with changes in the cardiac non-myocyte cellular composition
    Charles D. Cohen, Miles J. De Blasio, Man K.S. Lee, Gabriella E. Farrugia, Darnel Prakoso, Crisdion Krstevski, Minh Deo, Daniel G. Donner, Helen Kiriazis, Michelle Flynn et al. · 2021 · Cardiovascular Diabetology
  73. PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts
    Matthias L. Riess, Reem Elorbany, Dorothée Weihrauch, David F. Stowe, Amadou K.S. Camara · 2020 · Cells
  74. Cardiorenal syndrome and diabetes: an evil pairing
    Ana Belén Méndez, Ander Vergara, Aleix Olivella, Maria Antonieta Azancot, Toni Soriano-Colomé, María José Soler · 2023 · Frontiers in Cardiovascular Medicine
  75. Sodium bicarbonate loading limits tubular cast formation independent of glomerular injury and proteinuria in Dahl salt-sensitive rats
    Sarah R. McLarnon, Bansari Patel, Debra Lima Irsik, Jingping Sun, Hiram Ocasio, Gene Ryan Crislip, Chunhua Jin, Jian‐Kang Chen, Babak Baban, Aaron James Polichnowski et al. · 2018 · Clinical Science
  76. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments
    Katsuomi Iwakura · 2019 · Journal of Echocardiography
  77. Pre‐ and post‐diagnosis body mass index and heart failure mortality: a dose–response meta‐analysis of observational studies reveals greater risk of being underweight than being overweight
    Alireza Milajerdi, Kurosh Djafarian, Sakineh Shab‐Bidar, John Roger Speakman · 2018 · Obesity Reviews
  78. Humanistic and Economic Burden of Patients with Cardiorenal Metabolic Conditions: A Systematic Review
    Keith C. Ferdinand, Keith C. Norris, Helena W. Rodbard, Jennifer M. Trujillo · 2023 · Diabetes Therapy
  79. The E/e’ ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies
    Giacomo Zoppini, Corinna Bergamini, Alessandro Mantovani, Marco Dauriz, Giovanni Targher, Andrea Rossi, Enzo Bonora · 2018 · PLoS ONE
  80. A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics
    Shirley V. Wang, Judith C. Maro, Joshua J. Gagne, Elisabetta Patorno, Sushama Kattinakere Sreedhara, Danijela Stojanović, Efe Eworuke, Elande Baro, Rita Ouellet‐Hellstrom, Michael Nguyen et al. · 2021 · American Journal of Epidemiology
  81. Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus
    Gabriela Román, Anca Pantea Stoian · 2021 · IntechOpen eBooks
  82. Carbazoles: Role and Functions in Fighting Diabetes
    Fedora Grande, Giuseppina Ioele, Anna Caruso, Maria Antonietta Occhiuzzi, Hussein El‐Kashef, Carmela Saturnino, Maria Stefania Sinicropi · 2022 · Applied Sciences
  83. Left atrial strain evaluation to assess left ventricle diastolic dysfunction and heart failure with preserved ejection fraction: a guide to clinical practice
    Mariana Ribeiro Silva, Francisco Sampaio, Joana Braga, José Ribeiro, Ricardo Fontes‐Carvalho · 2023 · The International Journal of Cardiovascular Imaging
  84. Ginsenoside Rb1 ameliorates lipotoxicity-induced myocardial injury in diabetes mellitus by regulating Mfn2
    Louyin Ji, Hui Han, Xiaoli Shan, Pei Zhao, Huihua Chen, Chen Zhang, Ming Xu, Rong Lü, Wei Guo · 2024 · European Journal of Pharmacology
  85. Recent achievements and future directions of anti-obesity medications
    Gerald Grandl, Aaron Novikoff, Xue Liu, Timo D. Müller · 2024 · The Lancet Regional Health - Europe
  86. How Diabetes and Heart Failure Modulate Each Other and Condition Management
    Varinder K. Randhawa, Savita Dhanvantari, Kim Alexander Connelly · 2020 · Canadian Journal of Cardiology
  87. A novel model of cardiovascular–kidney–metabolic syndrome combining unilateral nephrectomy and high-salt–sugar–fat diet in mice
    Lucas Rannier Ribeiro Antonino Carvalho, Miho Shimari, Ariela Maína Boeder, Zhengbing Zhuge, Min Cai, Cecilia Leijding, Stefano Gastaldello, Andrei L. Kleschyov, Tomas A. Schiffer, Drielle D. Guimarães et al. · 2024 · Lab Animal
  88. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
    Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, Katharine D. Barnard-Kelly, Tadej Battelino, Matthias Blüher, Luca Busetto, Doina Catrinou, Antonio Ceriello, Xavier Cos et al. · 2025 · Cardiovascular Diabetology
  89. Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases
    Sebastian Steven, Marin Kuntić, Thomas F. Münzel, Andreas Daiber · 2025 · Pharmacological Reviews
  90. Needle-shaped glucose sensor based on polypyrrole doped with glucose oxidase
    Bao Li Zhang, Xuan Jin, Long Hua Sun, Xin Dong Guo · 2020 · Microchemical Journal
  91. Mesenchymal stem cells ameliorate inflammation and pyroptosis in diabetic cardiomyopathy via the miRNA-223-3p/NLRP3 pathway
    Yang Qu, Qi Chen, Sihui Li, Jun Luo · 2024 · Diabetology & Metabolic Syndrome
  92. Increased fractal dimension of left ventricular trabeculations is associated with subclinical diastolic dysfunction in patients with type-2 diabetes mellitus
    Yongning Shang, Xiaochun Zhang, Weiling Leng, Xiaotian Lei, Liu Chen, Xiaoyue Zhou, Kelvin Chow, Yanshu Shi, Jianlong Dong, Ziwen Liang et al. · 2018 · International journal of cardiac imaging
  93. Chronic heart failure and type 2 diabetes: state of the problem
    Andrey E. Bagriy, Evgeniy V. Suprun, E. S. Mykhailichenko, I.A. Golodnikov Golodnikov · 2020 · Russian Journal of Cardiology
  94. Metformin in patients with type 2 diabetes mellitus and heart failure: a review
    Zofia Kułaczkowska, Marta Patrycja Wróbel, Dominika Rokicka, Mariusz Gąsior, Krzysztof Strojek · 2021 · Endokrynologia Polska
  95. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)
    Irina Evgen'evna Chazova, Marina Vladimirovna Shestakova, Yu. V. Zhernakova, Nataliya V. Blinova, Т. Н. Маркова, Natalya Valentinovna Mazurina, Ежов Марат Владиславович, Sergey N. Tereshchenko, И. В. Жиров, Andrey L. Komarov et al. · 2021 · Eurasian heart journal
  96. Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction
    Oksana M. Drapkina, Olga N. Dzhioeva · 2020 · CARDIOVASCULAR THERAPY AND PREVENTION
  97. Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis
    Michele Correale, Stefania Paolillo, Valentina Mercurio, Gaetano M. Ruocco, Carlo Gabriele Tocchetti, Alberto Palazzuoli · 2021 · Kardiologia Polska
  98. Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
    Pedro F. Monteiro, Carlos Aguíar, Pedro Lucas Pereira Matos, José Silva‐Nunes, Rita Birne, Patrícia Quadros Branco, Joaquim Calado, Miguel Melo, Jorge Junqueira Polónia · 2019 · Revista Portuguesa de Cardiologia (English Edition)
  99. Chinese herbal medicine and active ingredients for diabetic cardiomyopathy: molecular mechanisms regulating endoplasmic reticulum stress
    Lianjun Ao, Zhengtao Chen, Jiacheng Yin, Yulin Leng, Yue Luo, Xiaoxu Fu, Hanyu Liu, Xiaoke Liu, Hong Gao, Chunguang Xie · 2023 · Frontiers in Pharmacology
  100. Series: Implications of the recent CVOTs in type 2 diabetes
    André Jacques Scheen · 2019 · Diabetes Research and Clinical Practice